Sentences with phrase «with prostate cancer therapy»

Not exact matches

The therapy had an outsized effect in African American men, helping those with metastatic castrate - resistant prostate cancer live a median 37.3 months after treatment.

Around four - fifths of prostate cancer patients have tumors with lots of PSMA for the therapy to bind to.

The Bottom Line: The study's researchers believe that the combination of cruciferous vegetables like cauliflower or broccoli with curcumin can be an effective therapy to both prevent prostate cancer altogether and to prevent the spread of prostate cancer that has already developed.

Disney said the precise binding of Targapremir - 18a to microRNA - 18a means a cancer drug that follows this strategy would be likely to kill prostate cancer cells without causing the broader side effects seen with many other cancer therapies.

There was also no change based on whether patients had undergone hormone therapy, a common treatment for prostate cancer which lowers the male hormone and can be combined with daily radiation.

Overall, about one - third of men with prostate cancer receive some type of radiation therapy.

To be effective and reduce recurrence of cancer in the prostate, researchers found that prescribing PARP inhibitors, a drug commonly used in breast cancer, alongside anti-hormone therapy treatment may benefit men with prostate cancer.

During this in depth study, an international team of researchers led by British scientists investigated the impact of anti-hormone therapy on samples taken from patients with prostate cancer.

The results from the Cancer Research UK - funded STAMPEDE trial could change the standard of care for men with prostate cancer, making abiraterone a first - line treatment alongside hormone thCancer Research UK - funded STAMPEDE trial could change the standard of care for men with prostate cancer, making abiraterone a first - line treatment alongside hormone thcancer, making abiraterone a first - line treatment alongside hormone therapy.

Radiation therapy, along with surgery, hormone therapy, and active surveillance — known as watchful waiting — has been a mainstay of treatment for prostate cancer in the United States.

Despite complications sometimes more severe than with standard radiation therapy — and costs that are much higher for taxpayers, patients and insurers — proton beam therapy is heavily marketed for treatment of prostate cancer.

A new study has identified a group of molecules in prostate - cancer cells that doctors might one day use to distinguish which patients should be treated with radiation therapy if rising PSA levels indicate their cancer has recurred after surgical removal of the prostate.

Using data from a randomized trial of 206 men treated with either radiation or, radiation and six months of hormonal therapy, researchers compared early markers of prostate cancer death to identify men at risk of dying early.

The findings inject hard facts into a debate that has long divided the medical community, with many radiation oncologists preferring adjuvant therapy — radiation given soon after prostate removal to kill off any remaining cancer cells — and many urologists preferring salvage therapy — radiation given later, when prostate - specific antigen tests suggest it's needed.

For men with intermediate risk prostate cancer, side effects at two years following radiation therapy (RT) were comparable for extremely - hypofractionated treatment, which was delivered in seven fractions across two and a half weeks, and conventional treatment of 39 fractions across eight weeks, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

«Depressed men with prostate cancer are diagnosed with later stage disease, and get less effective therapies.»

«We found that the protein isoforms expressed in African Americans with prostate cancer do not always respond to targeted therapies, whereas these drugs were found to be effective in European Americans with prostate cancer and do end up killing off the cancer,» said Lee.

«A significant number of advanced prostate cancer patients treated with a chemical castration therapy called androgen deprivation therapy (ADT) experience relapse with relentless progression to lethal metastatic, castration - resistant prostate cancer,» said Ronald DePinho, M.D., professor of Cancer Bicancer patients treated with a chemical castration therapy called androgen deprivation therapy (ADT) experience relapse with relentless progression to lethal metastatic, castration - resistant prostate cancer,» said Ronald DePinho, M.D., professor of Cancer Bicancer,» said Ronald DePinho, M.D., professor of Cancer BiCancer Biology.

In May 2015, the Moffitt Cancer Center launched a pilot study to test whether this kind of adaptive - therapy approach might help people with prostate cCancer Center launched a pilot study to test whether this kind of adaptive - therapy approach might help people with prostate cancercancer.

The finding, reported by a Stand Up to Cancer - Prostate Cancer Foundation Dream Team in the May 21 edition of the journal Cell, is based on an analysis of tumor samples from 150 men with metastatic prostate cancer that no longer responded to standard hormone - blocking thCancer - Prostate Cancer Foundation Dream Team in the May 21 edition of the journal Cell, is based on an analysis of tumor samples from 150 men with metastatic prostate cancer that no longer responded to standard hormone - blocking Prostate Cancer Foundation Dream Team in the May 21 edition of the journal Cell, is based on an analysis of tumor samples from 150 men with metastatic prostate cancer that no longer responded to standard hormone - blocking thCancer Foundation Dream Team in the May 21 edition of the journal Cell, is based on an analysis of tumor samples from 150 men with metastatic prostate cancer that no longer responded to standard hormone - blocking prostate cancer that no longer responded to standard hormone - blocking thcancer that no longer responded to standard hormone - blocking therapy.

A large trial showing that men with newly diagnosed, advanced prostate cancer lived ten months longer, on average, when they received docetaxel chemotherapy along with standard hormone therapy

«This approach may allow tailoring of clinical decisions regarding management of patients with prostate cancer, thus maximizing the benefit and minimizing the harms of therapy,» Roy said.

The research team used data from the recently published EORTC 22991 trial to study men with intermediate - risk prostate cancer randomized to either radiation therapy or radiation therapy and 6 months hormone therapy.

ADT, which suppresses the production of testosterone by either medical or surgical castration, remains the gold standard for treating advanced prostate cancer, either alone or with radiation therapy.

Of these men, 284 had prescriptions for testosterone replacement therapy before they were diagnosed with prostate cancer.

Presenting these results at the 3rd ESTRO Forum in Barcelona, Spain, today (Monday) Professor James Morris, from the Department of Radiation Oncology, Vancouver Cancer Centre, British Columbia Cancer Agency (BCCA), Vancouver, Canada, will say that the ASCENDE - RT1 trial is the first and only existing trial comparing low - dose - rate prostate brachytherapy (LDR - PB) for the curative treatment of prostate cancer with any other method of radiation therapy delCancer Centre, British Columbia Cancer Agency (BCCA), Vancouver, Canada, will say that the ASCENDE - RT1 trial is the first and only existing trial comparing low - dose - rate prostate brachytherapy (LDR - PB) for the curative treatment of prostate cancer with any other method of radiation therapy delCancer Agency (BCCA), Vancouver, Canada, will say that the ASCENDE - RT1 trial is the first and only existing trial comparing low - dose - rate prostate brachytherapy (LDR - PB) for the curative treatment of prostate cancer with any other method of radiation therapy delcancer with any other method of radiation therapy delivery.

The authors focused on men newly diagnosed with localized (non-metastatic) prostate cancer in 1995 - 2011 and treated with radical prostatectomy, brachytherapy, radiation therapy, or primary androgen deprivation therapy (PADT).

All enrolled patients had metastatic prostate cancer that was worsening despite treatment with traditional hormone therapy.

Men with low levels of the male sex hormone testosterone need not fear that testosterone replacement therapy will increase their risk of prostate cancer.

«Surprise: High - dose testosterone therapy helps some men with advanced prostate cancer.»

All had been treated previously with at least one type of androgen deprivation therapy and had rising levels of prostate specific antigen (PSA), a blood marker for prostate cancer, and radiographic evidence their cancers were becoming resistant.

Their records were compared with 192,838 men who did not develop prostate cancer, of whom 1,378 had used testosterone therapy.

«A retrospective analysis of the CHD1 gene in these samples may reveal the potential utility of CHD1 as a biomarker for improved prostate cancer patient stratification and targeted therapy with PARP inhibitors,» notes Johnsen.

In a second therapy commonly used for men with prostate cancer, doctors administer the female sex hormone oestrogen, which counteracts the androgens.

Preliminary results of a study of patients with prostate cancer show that MR tractography may be a reliable quantitative imaging biomarker to assess prostate cancer treatment response to androgen deprivation and radiation therapy, according to a team of researchers at Brigham and Women's Hospital and Massachusetts General Hospital in Boston.

Of the nearly 200,000 men diagnosed with prostate cancer each year in the United States, radiation is a first - line therapy considered for all but the most advanced disease.

The anxiety and uncertainty that men who choose active surveillance experience when diagnosed with prostate cancer causes one in four to receive definitive therapies within one to three years, even when there is no sign of tumor progression.

A new population - based study from The University of Texas Medical Branch at Galveston showed for the first time that exposure to testosterone therapy over a five - year period was not associated with an increased risk of aggressive prostate cancer.

Studies have found that women treated with radiation therapy for uterine cancer, like men who received radiation therapy for prostate cancer, have an increased risk of developing bladder cancer later in life.

Looking ahead, Chen says, «Ga -68-BBN-RGD could play an additive role in staging and detecting prostate cancer and provide guidance for internal radiation therapy using the same peptide labeled with therapeutic radionuclides.»

Since most men with prostate cancer have indolent (non-aggressive) disease for which conservative therapy or surveillance would be appropriate treatment, the clinical challenge is not only how to identify those with prostate cancer, but also how to distinguish those who would benefit from surgical or other aggressive treatment from those who would not.

The majority of men diagnosed with prostate cancer have low risk disease and face a difficult decision between having the disease managed conservatively through AS or undergoing definitive therapy.

The research, led by Daniel Krauss, M.D., a radiation oncologist, Beaumont Hospital — Royal Oak, found an association between positive post-radiation therapy biopsy results and subsequent clinical outcomes in men with localized prostate cancer.

This is the first population - based study to compare the follow - up intensity of American men with prostate cancer who have not undergone aggressive treatment with those who opted to undergo various forms of aggressive therapy, such as surgery and radiation.

Management of low risk prostate cancer with AS appears feasible and safe, yet most men in the U.S. with low risk disease still undergo definitive therapies such as radical prostatectomy, which carry the burden of urinary, bowel, and sexual dysfunction that can be avoided, or at the very least postponed, with management on AS.

«While each of these genes was independently associated with metastatic prostate cancer, they have never been studied together in the context of early detection of patients with prostate cancer that will relapse after localized therapy with curative intent, «according to the authors, led by Leigh Ellis, PhD, in the Dana - Farber Department of Oncologic Pathology.

Androgen deprivation therapy (ADT) is a common treatment option for patients with advanced stage prostate cancer.

• The incidence of prostate cancer metastasis was 14.5 percent for patients who received both treatments, compared with 23 percent for those who had only radiation therapy.

Many men diagnosed with prostate cancer receive hormone - blocking therapy as part of their treatment.

«We urgently need markers to predict which therapies are going to be effective and which will not be effective in individual patients with advanced prostate cancer,» said lead study author Emmanuel Antonarakis, MD, an assistant professor of oncology and urology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Md. «AR - V7 testing may be extremely valuable in guiding treatment decisions for men with hormone - resistant disease in the near future.&cancer,» said lead study author Emmanuel Antonarakis, MD, an assistant professor of oncology and urology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Md. «AR - V7 testing may be extremely valuable in guiding treatment decisions for men with hormone - resistant disease in the near future.&Cancer Center at Johns Hopkins in Baltimore, Md. «AR - V7 testing may be extremely valuable in guiding treatment decisions for men with hormone - resistant disease in the near future.»